Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
There is a huge international market for this company's products. The real home run will be when they get clearance for the collafix line. The possibilities are endless, just on the orthopedic side. Imagine a surgeon being able to reconstruct any tendon or ligament with a material that has the same specific properties of which they are replacing! Hand surgeons and sports guys will be all over these products! No risk for infection compared to allografts, matching biological properties specific to the injury site, matching sizes and shapes, the list goes on. The biggest concern is reimbursement, and that pertains to both US and international. If that can be worked out, I have no concerns about MDXG.
Very strong report. I think the only thing holding this back is the balance sheet. If they hit profitability before EOY, it will be huge. The industry is relatively new but gaining momentum and acceptance. I'm looking forward to watching this one grow!
How are sales numbers compare to Redchip's report?
Once the numbers come out, we will have definitive answers to all the questions. At this point, any of our best guesses hinges on what current inventory levels are at XCHO. I know this is basic, but it will be the most accurate way to tell if product is moving. I will also be looking to hear if, when and how much they plan to restock and place another large order with NPHC.
On another note, I hear differing opinions on the Walgreen's 2-4-1. Can someone show where this was planned? I am not in retail, so I don't know what to make of the offer. Is it Walgreen's clearing the shelves or is it just a marketing effort. Someone posted Walgreen's is paying for the second bottle. Where is this information coming from (and please don't say "from an email")?
I saw the same thing today in Tampa.
I think most of us lost a chunk today. XCHO is on thin ice with NPHC; that is clear from the language in the NPHC pr. The add campaign had better pick up and results need to be seen quickly. Let's see how the XCHO numbers look. Inventory and reorders will be a focus for me. Lets hope they were moving product and didn't restock their own supply with NPHC.
Still haven't seen or heard an add. Anyone been lucky to catch one?
I think its a little early to say Cobroxin "failed". If anything, it has made an impressive launch. I don't profess to know the history of success for OTC pain relievers, but I for one think Cobroxin had made serious inroads since becomming available late last year. We will see what the reorder rates are soon. That will give us a better idea of where this product is heading. After that, wait to see what the effect of the advertising has on Q3 sales. At that point we those that care can bump their chests or hide in a hole, depending on their current bullish or bearish sentiments.
Still yet to see, or hear, if anyone has seen a commercial on anything other than Hallmark. Did I miss a post?
Nice shots of the POW logo with Stan's appearance in Entourage tonight. Couldn't tell if it's going to develop as Vince's character is coming into question. Hopefully it's a good storyline that builds into a red carpet premier for Vince and Stan.
Shocker.
Fact? I'll just say I like that Ronald Mc Donald pic.
Better than 12% down everyday, right? Not sure where I heard that, but it was somewhere on thus board yesterday. Wasn't it? Does that mean next thing I will hear on this board is 12% up every day?
Yes, those that have been on the board for a while have been quite accurate. I used a lot of that as a starting point and it is much appreciated. I have done my own dd and the Redchip report reaffirms my thoughts (and position).
GLTA
Or, cool beans. Heading to the Gulf this weekend. No oil here!
Read the report in full. About what I was hoping to hear. Glad to be long.
Last day of the month and a Friday. No worries about volume.
That's my thinking as well. I took a position about 6 weeks ago and am pleased with the recent move. I believe it will be easy to make money in the short term once the legislation passes, I believe the real money will be made long term as the company expands.
Nice move today. As with so many other stocks right now, Washington seems to be the deciding factor on pps. If the revised bill passes, it will be a true launching pad for CLNE. If it gets shot down, it will no doubt mean (at least) a short term slide.
Saw another potential use for the collagen product today:
Sometimes when a patient needs a total shoulder but the surgeon feels the are too young and/or too active, they may use a technique that requires the use of an Achilles tendon allograft to cover the affected glenoid instead of using a polyethylene component to resurface the glenoid. Mimedx, based on their technology, can make a sheath configurations in different thicknesses and strengths, this could be a very viable option for this type of procedure. It would eliminate all the obvious problems with using an allograft and allow for a stronger more reliable and specific product that would be more better designed to a surgeons liking for manipulation, thickness and sizing.
Mimedx is a company that appears to have the right management in place. They have a groundbreaking and proprietary technology with almost limitless possibilities. Clear the financial and regulatory hurdles (which are still out there but according to the company being handled accordingly), and the sky is the limit.
Of course, I have to wait to Aug. 23rd for the JCG announcement. Specialty retailers (especially footware) appear to be doing very well with Deckers beating and raising FY outlook last week.
Buy what you buy! Come on retail sector. We know you have it in you.
I would agree.
I think so. I have no idea why you would have been banned. Just a thought after seeing a rival board on your message.
Of the retail chains listed check Rite Aid, as it is not in BOLD (noting it currently has the product) when listed in the three tables that show the largest retail chains by various categories. Rite Aid is in BOLD (noting the same as above) in the list of retail stores that have current contracts with Xenacare (some currently don't shelve the product).
Thoughts after conference call on Friday:
There are four things that stuck out in my mind after listening to the CC.
1) Missing the earnings projection for last quarter is not a huge deal to the company. The problems that are associated with rolling out a new product are seem endless these days and the company hit on many of these reasons: Validation Committees that approve use in hospitals/surgery centers instead of surgeons, complicated processes to get cleared in overseas markets and stabilizing local and international distribution channels, to name a few. MiMedx seems to understand these obstacles and appears to be addressing them appropriately.
2) With the miss on revenues, the company will need to raise more capital. Young companies often have financing hurdles. The company doesn't seem to think the amount is all that significant and will not have a problem raising the cash needed until the breakeven is achieved. Also, the drive to get listed on a larger exchange is certainly a focus for MiMedx and will help with gaining exposure and future funding as well as increasing shareholder value.
3) Product acceptance appears to be high both among distributors and surgeons. This is crucial to keep both the sales force motivated and to have surgeons willing to try a new product. With the challenges listed above, products can flounder and be forgotten by both the sales force and surgeons quite easily when products cannot be used. As long as the products are approved for use (both by FDA for the collagen line and in hospitals/surgery centers for all products) in the near future, this should not be a long-term concern.
4) The company sees an ever-expanding list of applications for their currently and future approved products. This is the most exciting and important item in my view. Cost effective, safe products are needed now more than ever and MiMedx has a developing product line that should be strong and diverse among several sectors of the industry. It sounds like many of these applications can be derived from current production technology and should not be difficult to develop. It will, however, be interesting to see how they decide to promote over such a wide spectrum as the industry currently is subdivided by specialties within the sales teams. How they partner with large companies and use distributor networks will be watched closely. There is more than one way to market these products and from the corporate team they have assembled, it appears they will do whatever it takes to use the most effective channels.
Of course, all of the above is just my opinion and anyone reading this must do their own DD and make informed investment decisions on their own.
Here's to solid execution down the road.
You may have to be careful about using other board names even if you are just re-posting your own stuff. Looks like it's back up.
The big deal is stock prices are based on what the company is expected to look like in the future. That's why when company XYZ blows out their quarter numbers but lowers guidance for the following quarter the stock drops. Hence this news is seen as a positive for future earnings.
But those watching Fox don't want to increase taxes on the cap gains you're going to realize after this year...lol! Seriously, the advertising blitz is welcome and shows they are ready to make the next big step with product being on the shelves. I'm sure they have done the research to find their target audience. It apparently worked with the Hallmark Channel decision.
Stan Lee was in the preview for next week's Entourage shaking Vince's hand. Maybe he'll pitch one of the new POW! characters to Vince and E.
I added on the dip. I am looking forward to the pc for a couple reasons: as an investor and as a possible distributor for the CollaFix products. Of course, if things work out on that aspect I won't be allowed to post any more, but we should all be happy if that opportunity is in the near future.
That's why I swing by JCrew once every couple weeks. Well, that has more to do with my wife liking it I guess, but that just makes it an easy double play.
Something to listen to (most likely)prior to NPHC conference call:
Henry Schein to Webcast Second Quarter 2010 Conference Call Monday, August 2, at 10:00 a.m. EDT
MELVILLE, N.Y., July 20, 2010 /PRNewswire via COMTEX/ --
Henry Schein, Inc. (Nasdaq: HSIC), the largest provider of health care products and services to office-based practitioners, announced today that it will release its second quarter 2010 financial results before the stock market opens on Monday, August 2, 2010, and will provide a live webcast of its earnings conference call on the same day beginning at 10:00 a.m. Eastern Daylight Time. Speakers on the call will include Stanley M. Bergman, Chairman and Chief Executive Officer of Henry Schein, and Steven Paladino, the Company's Executive Vice President and Chief Financial Officer.
It's a very intersting list and certainly one that can be used to start some good research. However, as someone in the healthcare sales industry there is a lot of DD needed here. On top of the obvious "potential" due to FDA clearance and early stage clinical trials that need to prove effective there are more imminent issues. These include, but are not limited to, healthcare reform legislation that still casts uncertainty for reimbursement new technologies, hospital budgets and more importantly the new "product review boards" that hospitals use to see if they will let doctors use certain products and surgeon acceptance and use, to name a few.
I am a big proponent of investing in the healthcare sector. I have had some hits (MDXG from .40 to 1.70 at sell) and some misses (XCHO from .28 to .18-but still holding and now averaged at .26) This is just a heads up to make sure you always do your DD and ALWAYS protect your unit.
You're exactly right, Savannah.
We have a saying here that is very appropriate in this case:
This post come from way out in left field. It has no credence, IMHO, and should be ignored.
Yes, is that hopeful thinking or is there some reason to believe an announcement will happen today?
Has anyone been watching this run-up? 45% in a about a week? Any insight? L2 evaluation anyone?
Thank you. I have been looking for re news that brought on this pop.
It sure is easy to see who does their DD around here.
No. Just a way to see how the sector has performed and what forward looking statements may come from an industry heavyweight ie. Intel's numbers can be used to see how other chipmakers, their suppliers and their customers may possibly be doing.